MannKind | MNKD - Actif À Court Terme





Actif À Court Terme Changement Date
Adma Biologics USD 511.17M 44.66M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 182.52M 37.42M 2026-03
MannKind USD 251.16M 40.42M 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Novavax USD 850.82M 127.46M 2026-03
Novo Nordisk DKK 25.71B 148.69B 2025-06
Pfizer USD 42.82B 76M 2026-03
Sanofi EUR 30.16B 789M 2026-03
Xencor USD 482.85M 116.97M 2026-03